Markets
BSE See NSE See 48,939.42
-2,099.89 (-4.11%)

Glenmark Pharma enters into exclusive agreement with Menarini Group; stock ends positively

chinmayee d / Article rating: 4.3

Under this agreement, Glenmark Pharma will be responsible for the development & regulatory approval of the nasal spray by relevant European Regulatory Authorities whereas, Menarini Group will be responsible for the commercialisation of Ryaltris across these markets. 

First567810121314Last

DSIJ MINDSHARE

12345Last

Knowledge

12